KPV Dosage Chart and Calculator: Common Protocol, Animal Data
KPV dosage chart: units per dose by vial size for the 200-500 mcg common protocol, a calculator for reconstitution, and the published mouse studies.
The short version
No published human trial of KPV exists, at any dose, for any indication. FDA's July 2026 review found the same gap, so no trial or regulator has set a dose. Vendor dosing guides most often describe 200-500 mcg by subcutaneous injection, once or twice daily, for 4-8 weeks - common practice, not trial-established. The only other dosing data come from mouse studies, and the abstracts I read give no exact amounts.
- Common practice is 200-500 mcg subcutaneous, once or twice daily, in 4-8 week cycles with a 2-4 week break - not trial-established.
- No published human trial of KPV exists, at any dose, for any indication.
- The published dosing data come from mouse studies, and the abstracts I read give no exact amounts.
- FDA found no human exposure data for KPV, by any route, in its July 2026 review.
KPV has no approved dose and no published human study behind it. FDA’s July 2026 review found nobody has ever given KPV to a human in a documented study, by any route. This page gives the protocol vendor dosing guides commonly describe and the animal dosing details in the published record, and explains why neither can become a human dose. For what KPV is, how it works and FDA’s full review, see the main KPV guide.
US legal status - Research use only
KPV has no FDA-approved product, no approved dose, and (per FDA's own July 2026 review) no published human trial of any kind.
KPV dosage: the common protocol
Vendor dosing guides most often describe 200-500 mcg by subcutaneous injection, once or twice daily, for a 4-8 week cycle with a 2-4 week break. That is common practice, not a dose any trial or regulator has established.
Common protocol
What is commonly used, not a dose established in trials. No regulator has set a dose for KPV.
- Dose per administration
- 200-500 mcg
- How often
- once or twice daily, subcutaneous injection, rotating sites
- Route
- Subcutaneous injection
- Cycle length
- 4-8 weeks
- Break between cycles
- 2-4 weeks
- Common vial size
- 10 mg
- Timing
- Consistent daily timing; subcutaneous (one named clinic also offers intramuscular) with injection sites rotated between abdomen, thigh and upper arm.
- Commonly paired with
- BPC-157, TB-500, Thymosin alpha-1, LL-37
Upgraded 2026-09-27: replaced the Path To Peptides vendor page with Beverly Hills Rejuvenation Center (BHRC), a named multi-location physician-led clinic, whose protocol independently confirms the same 200-500 mcg, 1-2x daily, 4-8 week-cycle numbers and the BPC-157/Thymosin Alpha-1/LL-37 pairings. BHRC also offers intramuscular as an alternative route and cites a 10 mg standard vial, vs. the remaining vendor source's 5 mg vial - vial size varies by supplier/pharmacy. The remaining source (thekpvpeptide.com), an informational/educational site that states it is not affiliated with any peptide vendor and is not itself a vendor despite the compound-name domain, is kept for the TB-500 pairing, the 2-4 week break period, the acute-dose escalation, and the oral/topical protocols, none of which BHRC's page addressed.
Plan a cycle in the protocol builder or work out injection volume in the dosage calculator.
The common KPV dose is 200-500 mcg, once or twice daily, subcutaneous injection, rotating sites. From a 10 mg vial mixed with 2 mL of bacteriostatic water, 350 mcg is 7 units (0.07 mL) on a U-100 insulin syringe.
KPV 10 mg vial: units per dose
Full 10 mg vial page: mixing, doses per vial, how long it lasts →
| Water added | Concentration | 1 unit = | 200 mcg | 350 mcg | 500 mcg |
|---|---|---|---|---|---|
| 1 mL | 10 mg/mL | 100 mcg | 2 units | 3.5 units | 5 units |
| 2 mL | 5 mg/mL | 50 mcg | 4 units | 7 units | 10 units |
| 3 mL | 3.33 mg/mL | 33.33 mcg | 6 units | 10.5 units | 15 units |
All KPV vial sizes: 10 mg
Units are on a standard U-100 insulin syringe (100 units = 1 mL), rounded to the nearest half unit - half-unit marks are on 0.3 mL syringes. Water volumes are examples: more water means more units per dose, not more doses per vial. For any other vial or dose, use the calculator below.
How many 10 mg vials a cycle takes
| Scenario | Dose | Doses a week | Weeks | Total | 10 mg vials |
|---|---|---|---|---|---|
| Low end of the common protocol | 200 mcg | 7 | 4 | 5.6 mg | 1 |
| High end of the common protocol | 500 mcg | 14 | 8 | 56 mg | 6 |
Whole vials, rounded up. Plan a cycle with your own numbers in the protocol builder. Keep mixed vials cold and use them within the window in how long reconstituted peptides last; where to inject: subcutaneous injection sites.
No published human study exists
I could not find a published human trial of KPV, at any dose, for any indication. The main KPV guide reaches the same conclusion, citing FDA’s July 2026 briefing document for the Pharmacy Compounding Advisory Committee. That document says neither KPV’s nominator nor FDA identified any clinical study or human exposure data, by any route. No human “dosing protocol” for KPV traces to a study this page could fetch and verify.
KPV doses used in animal studies
A 2008 study Dalmasso 2008 - Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78., in the references below gave KPV orally, added to the drinking water, to mice with colitis induced by dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS). It reduced signs of intestinal inflammation, including pro-inflammatory cytokine expression, compared with untreated colitis controls. The same paper reports that nanomolar concentrations of KPV block NF-kappaB and MAP kinase inflammatory signalling in human intestinal cell lines in vitro. It also reports that KPV is taken up into cells via the PepT1 transporter.
Two other mouse studies dosed KPV:
- A 1989 study compared graded doses of the tripeptide with saline and a large dose of corticosteroid on chemically induced ear swelling. KPV reduced swelling in a dose-related way Hiltz 1989 - Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-4., in the references below.
- A second 2008 study treated two mouse colitis models, DSS and T-cell transfer colitis. KPV-treated mice recovered earlier, regained more weight and had fewer inflammatory infiltrates. In mice with a non-functional melanocortin-1 receptor, KPV prevented death from DSS colitis in every treated animal Kannengiesser 2008 - Kannengiesser K, Maaser C, Heidemann J et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31., in the references below.
What is not established
- No human dose exists, at any level, for any indication, because no published human trial of KPV exists.
- No human safety data exists. FDA found no acute, repeat-dose, genotoxicity, reproductive or carcinogenicity data for KPV or its acetate salt. The main guide has the full safety review.
- No human half-life or pharmacokinetic figure is established. FDA found no human absorption, distribution or clearance data for KPV, so no dosing interval can be built on one.
- The common protocol above is current vendor practice, not a trial finding. Each source is recorded, but no trial or regulator has established that dose.
Reconstitution and injection volume: use the calculator, not a guess
There is no human dose on this page to convert into an injection volume. If you are working out concentration or draw volume for a vial anyway, use the dosage calculator. It walks through vial strength, diluent volume and target amount. It does the math; it does not tell you what amount to target.
Who should not use it
No FDA-reviewed contraindication list exists, because KPV has never been the subject of a published human trial, let alone a regulatory review. With zero human data, there is nothing regulator-reviewed to weigh against pregnancy, breastfeeding, children, any diagnosed medical condition, or use alongside other medications. That absence of data is itself a reason for caution, not a reason to assume safety.
KPV side effects and risks
The main risk this page can document is the total absence of human evidence: no human trial, no human safety data, and no established human half-life or pharmacokinetics. FDA also flagged open questions about immunogenicity, aggregation, and how well characterised the marketed material is; the main guide has that detail. Material sold as KPV is a research chemical with no regulator-verified purity, identity or concentration.
Related
KPV dosage calculator
Preset to a 10 mg vial and 200 mcg, the low end of the common protocol. Enter your own vial size, water and dose to get the syringe units to draw.
Your vial
Printed on the vial. There is no standard size - enter what yours says.
This changes how much you draw - never how many doses the vial holds.
100 units per mL. 1 unit = 0.01 mL. This is what almost every insulin syringe sold is, in every barrel size.
Capacity only. A 1 mL U-100 syringe holds 100 units - the scale decides that, not the barrel.
Draw this much
= 0.04 mL on a 1 mL U-100 syringe
- Concentration
- 5,000 mcg/mL
- Exact volume
- 0.04 mL
- Dose you actually get
- 200 mcg
- Doses per vial(unaffected by water volume)
- 50
Where to buy KPV for research
Each vendor is checked against my vendor checklist.
1.Next Level PharmFeatured
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
- Takes card payment
2.BioEdge Research Labs
10 mg vial
- No FDA warning letter found
- Names its testing lab
- Batch COAs published
KPV capsules
Taken by mouth, and a different product from the vial: ask for a COA for the capsule batch.
- BioEdge Research Labs: 500 mcg capsules, 60 count$109.00 as of 3 October 2026 View →
Common questions
What is the usual KPV dose?
Vendor dosing guides most often describe 200-500 mcg by subcutaneous injection, once or twice daily, for a 4-8 week cycle with a 2-4 week break. Some sources also describe oral (500 mcg-2 mg) and topical (0.1-1% cream) versions. That is common practice reported by vendor pages, not a dose established by any trial or regulator. No human trial data exists at all (see the next question).
What dose of KPV have human studies used?
None. There is no published human trial of KPV, at any dose, by any route, for any indication. FDA's July 2026 briefing document reached the same conclusion: neither KPV's nominator nor FDA could find any clinical study or human exposure data.
Is there an FDA-approved KPV dose?
No. KPV has no FDA-approved product, no approved indication, and no dose established as safe or effective by any regulator.
What doses were used in animal studies?
A 2008 study added KPV to the drinking water of mice with colitis and found it reduced signs of intestinal inflammation. A 1989 study gave graded doses that reduced chemically induced ear swelling in a dose-related way. A second 2008 study treated two mouse colitis models. None of these abstracts reports the exact amount used, so this page does not print one.
Can the mouse dose be converted into a human one?
No. There is no accepted, verified method for converting a mouse drinking-water dose into a human amount, even where one is reported, and this page does not invent one. A mouse colitis model shows what happened in that model, not what would happen in a person.
How do I work out reconstitution and injection volume?
That is arithmetic about a specific vial and diluent, not a dosing decision, and no trial has set a human dose. The dosage chart on this page gives units for the common protocol by vial size. The dosage calculator does the concentration and draw-volume math for whatever amount you enter; it does not tell you what dose to use.
Who should not use KPV?
No FDA-reviewed contraindication list exists, because KPV has never been the subject of a published human trial, let alone a regulatory review. With zero human data, there is nothing regulator-reviewed to weigh against pregnancy, breastfeeding, any diagnosed condition, or use alongside other medications.
When should I stop and get medical care?
Get emergency care (call 911 in the US) for a severe allergic reaction, chest pain, fainting, or any symptom that feels dangerous. Call Poison Control at 1-800-222-1222 if you have taken an unknown or excessive amount of anything sold as KPV. None of this is a substitute for a clinician who knows your history.
References (4 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Dalmasso G, Charrier-Hisamuddin L, Nguyen HT et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78.StudyPMID 18061177full text
- 2.Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-4.StudyPMID 2550304
- 3.Kannengiesser K, Maaser C, Heidemann J et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31.StudyPMID 18092346
- 4.National Poison Control Center - 1-800-222-1222, free and confidential poisoning and overdose guidance; phone number confirmed on the organization's own page.- America's Poison Centersother